



HAL
open science

PfEMP1 A-Type ICAM-1-Binding Domains Are Not Associated with Cerebral Malaria in Beninese Children

Valentin Joste, Emilie Guillochon, J. Fraering, Bertin Vianou, Laurence Watier, Sayeh Jafari-Guemouri, Michel Cot, Sandrine Houzé, Agnès Aubouy, Jean François Faucher, et al.

► To cite this version:

Valentin Joste, Emilie Guillochon, J. Fraering, Bertin Vianou, Laurence Watier, et al.. PfEMP1 A-Type ICAM-1-Binding Domains Are Not Associated with Cerebral Malaria in Beninese Children. *mBio*, 2020, 11 (6), <10.1128/mBio.02103-20>. <hal-03032252>

HAL Id: hal-03032252

<https://hal.science/hal-03032252v1>

Submitted on 7 Dec 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.



L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons CC BY 4.0 - Attribution - International License



PfEMP1 A-Type ICAM-1-Binding Domains Are Not Associated with Cerebral Malaria in Beninese Children

V. Joste,^a E. Guillochon,^a J. Fraering,^a B. Vianou,^{a,b} L. Watier,^c S. Jafari-Guemouri,^a M. Cot,^a S. Houzé,^{a,d,e}  A. Aubouy,^f J. F. Faucher,^g N. Argy,^{a,d,e}  G. I. Bertin,^a NeuroCM study group

^aUniversité de Paris, MERIT, IRD, Paris, France

^bInstitut de Recherche Clinique du Bénin (IRCB), Cotonou, Bénin

^cDepartment of Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Inserm, UVSQ, Institut Pasteur, Université Paris-Saclay, Paris, France

^dParasitology Laboratory, Bichat-Claude Bernard hospital, Paris, France

^eMalaria National Reference Center, Bichat-Claude Bernard hospital, Paris, France

^fUniversité de Toulouse, PHARMADEV, IRD, UPS, Toulouse, France

^gUniversité de Limoges, NET, INSERM, Limoges, France

ABSTRACT PfEMP1 is the major antigen involved in *Plasmodium falciparum*-infected erythrocyte sequestration in cerebrovascular endothelium. While some PfEMP1 domains have been associated with clinical phenotypes of malaria, formal associations between the expression of a specific domain and the adhesion properties of clinical isolates are limited. In this context, 73 cerebral malaria (CM) and 98 uncomplicated malaria (UM) Beninese children were recruited. We attempted to correlate the cytoadherence phenotype of *Plasmodium falciparum* isolates with the clinical presentation and the expression of specific PfEMP1 domains. Cytoadherence level on Hbec-5i and CHO-ICAM-1 cell lines and *var* genes expression were measured. We also investigated the prevalence of the ICAM-1-binding amino acid motif and dual receptor-binding domains, described as a potential determinant of cerebral malaria pathophysiology. We finally evaluated IgG levels against PfEMP1 recombinant domains (CIDR α 1.4, DBL β 3, and CIDR α 1.4-DBL β 3). CM isolates displayed higher cytoadherence levels on both cell lines, and we found a correlation between CIDR α 1.4-DBL β 1/3 domain expression and CHO-ICAM-1 cytoadherence level. Endothelial protein C receptor (EPCR)-binding domains were overexpressed in CM isolates compared to UM whereas no difference was found in ICAM-1-binding DBL β 1/3 domain expression. Surprisingly, both CM and UM isolates expressed ICAM-1-binding motif and dual receptor-binding domains. There was no difference in IgG response against DBL β 3 between CM and UM isolates expressing ICAM-1-binding DBL β 1/3 domain. It raises questions about the role of this motif in CM pathophysiology, and further studies are needed, especially on the role of DBL β 1/3 without the ICAM-1-binding motif.

IMPORTANCE Cerebral malaria pathophysiology remains unknown despite extensive research. PfEMP1 proteins have been identified as the main *Plasmodium* antigen involved in cerebrovascular endothelium sequestration, but it is unclear which *var* gene domain is involved in *Plasmodium* cytoadhesion. EPCR binding is a major determinant of cerebral malaria whereas the ICAM-1-binding role is still questioned. Our study confirmed the EPCR-binding role in CM pathophysiology with a major overexpression of EPCR-binding domains in CM isolates. In contrast, ICAM-1-binding involvement appears less obvious with A-type ICAM-1-binding and dual receptor-binding domain expression in both CM and UM isolates. We did not find any variations in ICAM-1-binding motif sequences in CM compared to UM isolates. UM and CM patients infected with isolates expressing the ICAM-1-binding motif displayed similar IgG levels against DBL β 3 recombinant protein. Our study raises interrogations

Citation Joste V, Guillochon E, Fraering J, Vianou B, Watier L, Jafari-Guemouri S, Cot M, Houzé S, Aubouy A, Faucher JF, Argy N, Bertin GI, NeuroCM study group. 2020. PfEMP1 A-type ICAM-1-binding domains are not associated with cerebral malaria in Beninese children. *mBio* 11:e02103-20. <https://doi.org/10.1128/mBio.02103-20>.

Invited Editor Sean T. Prigge, Johns Hopkins Bloomberg School of Public Health

Editor Jon P. Boyle, University of Pittsburgh

Copyright © 2020 Joste et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to G. I. Bertin, gwlady.bertin@ird.fr.

Received 18 August 2020

Accepted 12 October 2020

Published 17 November 2020

about the role of these domains in CM physiopathology and questions their use in vaccine strategies against cerebral malaria.

KEYWORDS cerebral malaria, *var* genes, cytoadherence, dual receptor binding, ICAM-1-binding motif

Cerebral malaria (CM) is the most severe form of *Plasmodium falciparum* (*P. falciparum*) infection, mainly affecting children under 5 years in areas of endemicity (1). One of the most-described pathophysiologic mechanisms of CM is the ability of *P. falciparum*-infected erythrocytes (iE) to adhere to the cerebrovascular endothelium through variant surface antigen (VSA) proteins. These proteins are expressed on the iE cell membrane and bind to multiple endothelial receptors (2). In CM, this phenomenon causes brain swelling, coma, and even death (3). Currently, there is no specific marker for CM, but histopathology of malarial retinopathy (MR) (4, 5) correlates with cerebral pathology.

The major VSA involved in iE sequestration is *Plasmodium falciparum* erythrocyte membrane protein 1 (PfEMP1). This parasitic protein is encoded by *var* genes (6), a hypervariable multigenic family classified in four groups, A, B, C, and E, and two intermediate groups, B/A and B/C (7). PfEMP1 proteins from A (8, 9) and B/A (10) groups are associated with severe malaria (SM). PfEMP1 sequences are divided into two types of hypervariable extracellular domains: cysteine-rich interdomain regions (CIDR) and Duffy-binding-like (DBL). They have been classified into domain cassettes (DCs), composed of at least two conserved domains, DBL/CIDR (11).

Several studies on laboratory *P. falciparum* strains selected to adhere to brain microvascular endothelial cells have revealed preferential expression of certain PfEMP1 DCs such as DC8 (DBL α 2-CIDR α 1.1/8-DBL β 12-DBL γ 4/6) and DC13 (DBL α 1.7-CIDR α 1.4) (12, 13). These DCs are predicted to bind to endothelial protein C receptor (EPCR) (15) through CIDR α 1 domains (16) and are overexpressed in CM clinical isolates (10, 17–19). Importantly, inhibition of EPCR binding did not block the adherence of iE expressing DC8 and DC13 to brain endothelial cells, and EPCR binding alone is not sufficient to fully explain cytoadhesion level (20). These elements suggest the implication of another receptor in the cytoadherence mechanism.

Intercellular adhesion molecule 1 (ICAM-1) receptor has previously been proposed to be implicated in iE adhesion, and ICAM-1 overexpression in cerebrovascular tissue has been shown (21). Moreover, it has been demonstrated that EPCR and ICAM-1 are involved in iE binding to brain cells (22). In this context, an ICAM-1-binding amino acid sequence, found in A-type DBL β 1/3 domains and mainly associated with CM, was recently identified (23–25). Interestingly, each DBL β 1/3 domain predicted to bind ICAM-1 is preceded by an EPCR-binding CIDR α 1 domain which defines a dual receptor-binding PfEMP1 sequence, associated with CM (23). Jensen et al. proposed a pathogenic cascade where the iE first binds to EPCR, leading to a proinflammatory cytokine release and increased expression of ICAM-1 (26).

Despite extensive research, few formal associations between the expression of specific domains of PfEMP1 and the adhesion properties of clinical isolates of *P. falciparum* have been demonstrated (18, 19, 27). In order to fill this gap, we conducted a comparative study on CM and uncomplicated malaria (UM) in Beninese children, in which we attempted to correlate the cytoadherence phenotype of *P. falciparum* isolates with clinical presentation and the expression of specific domains of PfEMP1. We also focused on the ICAM-1-binding motif and its implication in CM pathogenesis.

RESULTS

Recruitment and sample description. A total of 171 patients were included, comprising 73 CM and 98 UM cases. Two UM cases were coinfecting with *Plasmodium malariae* and subsequently excluded from downstream analysis. Clinical and biological characteristics of recruited patients are described in Table 1. Compared to UM, CM patients presented a lower age and blood pressure and a higher pulse and respiratory rate ($P < 0.0001$). Moreover, CM patients had more frequent hepatomegaly ($P < 0.0001$)

TABLE 1 Clinical characteristics of the patients included during the study^a

	Cerebral malaria (<i>n</i> = 73)	Uncomplicated malaria (<i>n</i> = 96)	<i>P</i> value
Age (mo)	43.4 (29.9–63.2)	59.9 (36–70)	<0.0001
Gender, no. female/total no. (% female)	44/73 (60%)	42/96 (44%)	0.033
Pulse rate (beats/min)	152 (122.2–178)	120 (100–160)	<0.0001
Respiratory rate (beats/min)	48 (34.4–65.6)	40 (36–48)	<0.0001
Systolic blood pressure (mm Hg)	90 (70–100)	110 (100–120)	<0.0001
Parasitemia (parasites/ μ l)	60,900 (283–763,040)	39,180 (3,784–253,360)	
Hemoglobinemia (g/dl)	5.4 (3.3–8.7)	9.4 (7–11.3)	<0.0001
Leukocytes (G/liter)	12.8 (7.4–29.4)	7.2 (4.6–10.4)	<0.0001
Neutrophils (G/liter)	8.1 (3.9–17.9)	3.3 (1.8–6.6)	<0.0001
Lymphocytes (G/liter)	4.3 (1.7–11.1)	2.2 (1.1–4.1)	<0.0001
Platelets (G/liter)	85 (42.3–214.2)	177 (79.5–346.5)	<0.0001
Creatinine (mg/liter)	5 (2.8–8.2)	3 (3–4.3)	<0.0001
Total bilirubin (mg/liter)	26 (9.8–70.2)	9.3 (4.7–20.9)	<0.0001
Conjugated bilirubin (mg/liter)	13.4 (3.4–30.4)	4.3 (2–9.3)	<0.0001
Blood glucose (g/liter)	0.8 (0.1–1.3)	1 (0.8–1.3)	<0.0001
Urea (g/liter)	0.15 (0.1–0.37)	NA	
Lactates (mmol/liter)	6.2 (2.4–9.9)	NA	
Albuminemia (g/liter)	27 (21–33)	NA	
GPT (U/liter) ^b	38 (14–114)	NA	
Bicarbonates (mmol/liter)	14.8 (6–23.9)	NA	
Hepatomegaly (positive %)	53.4	9.5	<0.0001
Splenomegaly (positive %)	37	18.1	0.0046
Malarial retinopathy		NA	
Yes	35 (48)		
No	17 (23)		
Not evaluated	21 (29)		
Blantyre score			
0	1 (1.4)	NA	
1	22 (30.1)	NA	
2	50 (68.5)	NA	
3	0	NA	
4	0	NA	
5	0	NA	
Mortality (%)	34.8%	NA	

^aNonparametric results were represented as median (10th to 90th percentile) and proportions as *n* (%). Statistical differences between UM and CM were calculated using the Mann-Whitney U-test or the χ^2 test. Only significant *P* values of <0.05 were indicated. NA, nonattributable.

^bGlutamate-pyruvate transaminase.

and splenomegaly ($P = 0.0046$). Sixty-seven percent of diagnosed CM cases presented retinopathy. CM cases had lower hemoglobin and blood glucose concentrations, lower platelet counts, higher creatinine and bilirubin concentrations, and higher leukocyte counts ($P < 0.0001$). Notably, 35% of children with CM died in our study in spite of adequate management including parenteral treatment with artesunate. There was no difference in multiplicity of infection (MOI) between CM and UM isolates (4 [3 to 9] versus 4 [3 to 7]). Values in parentheses and brackets are median [10–90th percentile].

Cytoadherence of isolates on Hbec-5i and CHO-ICAM-1 cell lines. On Hbec-5i, the cytoadherence value was 63 (27 to 203) iE/mm² for CM isolates ($n = 21$) and 13 (7 to 62) iE/mm² for UM isolates ($n = 35$) ($P < 0.0001$). The cytoadherence assay was also performed on CHO-ICAM-1, for which the cytoadherence value was 107 (44 to 273) iE/mm² for CM isolates ($n = 15$) and 59 (4 to 108) iE/mm² for UM isolates ($n = 28$) ($P = 0.01$) (Fig. 1). In addition, cytoadherence levels on Hbec-5i and CHO-ICAM-1 cells were similar in CM isolates, while cytoadherence to CHO-ICAM-1 was higher in UM isolates ($P = 0.0005$). We performed cytoadherence assays with the HB3 strain selected on Hbec-5i or CHO-ICAM-1 cell lines. HB3-Hbec-5i and HB3-ICAM-1 displayed 22- and 7-times-higher cytoadherence values, respectively, than the median cytoadherence value of isolates. We also compared HB3-ICAM-1 cytoadherence values on both CHO-ICAM-1 and the parental CHO cell lines and demonstrated that ICAM-1 receptor explained at least 75% of cytoadherence on CHO-ICAM-1 cell lines.




FIG 1 Cytoadherence of UM and CM isolates. Median and interquartile range of bound infected erythrocytes (iE) are indicated. Hbec-5i cytoadherence was evaluated for 21 CM and 35 UM isolates. CHO-ICAM-1 cytoadherence was evaluated for 15 CM and 28 UM isolates. *P* values were calculated with Mann-Whitney U-test. *, *P* < 0.05; **, *P* < 0.01; ***, *P* < 0.0001; NS, nonsignificant.

var gene expression quantification. Our primer set displayed good coverage on the CIVIC and Pf3K data sets (see Table S1a and b in the supplemental material). All CM and UM isolates were typed for *var* gene expression (Table 2). CM isolates overexpressed EPCR-binding domains (CIDR α 1.1, CIDR α 1.4 to 1.8), ICAM-1-binding domain (DBL β 5), and double domains (CIDR α 1.4-DBL β 1/3, CIDR α 1.6-DBL β 1/3, CIDR α 1.7-DBL β 1/3) as well as domains without predicted binding characteristics (CIDR α 1.2, DBL ξ 3, DBL ϵ 2, DBL γ 1) compared to UM isolates. No difference was observed for CD36-binding domains (CIDR α 2.3/5/6/7/9/10), CIDR δ - and ICAM-1-binding DBL β 1/3 domain. Primers targeting DBL α 2/1.1/2/4/7 domains, predicted to precede EPCR-binding CIDR α 1, reported a higher level in CM isolates (*P* < 0.0001). We did not observe any difference in *var* genes domain expression between positive and negative MR patients (Table S2).

Associations between *var* genes expression were also evaluated. Expected connections (such as CIDR α 1.7 and CIDR α 1.7-DBL β 1/3) were observed. Interestingly, a significant correlation was shown between DBL ξ 3 expression and double domains in CM isolates (Fig. 2 and Table S3).

TABLE 2 Relative quantification of *var* gene transcript levels^a

Domain	Group	Predicted receptor	CM		UM		<i>P</i> value
			<i>n</i>	Median (10th–90th percentile)	<i>n</i>	Median (10th–90th percentile)	
CIDR α 1.1	B/A	EPCR	68	0.056 (0–1.16)	96	0.0041 (0–0.53)	0.0052
CIDR α 1.8	B/A	EPCR	70	0.00071 (0–0.075)	95	0 (0–0.018)	0.0029
CIDR α 1.4	A	EPCR	70	0.17 (0–3.7)	96	0.012 (0–1.1)	0.0020
CIDR α 1.5	A	EPCR	70	0.0057 (4.4 × 10 ⁻⁵ –0.071)	95	0.00063 (0 to 0.014)	<0.0001
CIDR α 1.6	A	EPCR	69	0.01 (0–0.13)	96	0.0020 (0–0.017)	0.00027
CIDR α 1.7	A	EPCR	69	0.0057 (0.00015–0.057)	85	0.001 (2.3 × 10 ⁻⁵ –0.0094)	<0.0001
CIDR α 1.2	A		69	0.0072 (0–0.036)	96	0.0033 (0–0.013)	0.010
CIDR δ	A		69	0.0088 (0–0.42)	96	0.0032 (0–0.12)	
CIDR α 2.3/5/6/7/9/10	B	CD36	70	0.00063 (0–0.0069)	95	0.00026 (0–0.0043)	
DBL α 1.7	A		66	0.14 (0–8.6)	92	0.12 (0–4.94)	
DBL α 2/1.1/2/4/7	A		70	0.43 (0.077–2.35)	95	0.15 (0.030–0.61)	<0.0001
DBL β 1/3-motif	A	ICAM-1	68	6.9 × 10 ⁻⁵ (0–0.19)	93	0 (0–0.088)	
DBL β 5	B	ICAM-1	69	0.022 (0–0.19)	96	0.0026 (0–0.11)	0.00062
DBL ϵ 2			69	0 (0–0.0034)	96	0 (0–0.0034)	0.011
DBL ξ 3			70	0.0025 (0–0.019)	96	0 (0–0.009)	<0.0001
DBL γ 1			70	0.0016 (0.0002–0.0081)	93	0.00042 (0–0.0032)	0.001
CIDR α 1.4-DBL β 1/3	A	EPCR ± ICAM-1	70	0.038 (0–0.31)	92	0.0046 (0–0.062)	<0.0001
CIDR α 1.6-DBL β 1/3	A	EPCR ± ICAM-1	70	0.017 (0–0.12)	95	0.0022 (0–0.040)	<0.0001
CIDR α 1.7-DBL β 1/3	A	EPCR ± ICAM-1	66	0.065 (0.00043–0.58)	90	0.0033 (0–0.059)	<0.0001

^aResults are expressed after normalization with P90 quantification. Nonparametric results are presented as median (10th to 90th percentile). Results were considered significant when *P* value was <0.05. *P* values were calculated with Mann-Whitney U-test. Only significant *P* values of <0.05 are indicated. Number of isolates (*n*) in the analysis is specified.




FIG 2 Chord diagram. Correlations between *var* genes expressions were calculated with Spearman rank test for CM isolates (A) and UM isolates (B). Only correlations with *P* value adjusted with Benjamini-Hochberg correction <0.1 are represented.




FIG 3 Children's IgG levels against DBL β ₃_{PF3D7_1150400}, CIDR α 1.4_{PF3D7_1150400}, and CIDR α 1.4-DBL β ₃_{PF3D7_1150400}. Mann-Whitney U-test was used to compare IgG levels for CM and UM patients. Values on y axis show ELISA arbitrary units (see Materials and Methods). Scatter plots with median and interquartile range are represented (UM, $n = 96$; CM, $n = 71$). *, $P < 0.05$; **, $P < 0.01$.

Partial correlation between cytoadherence and *var* gene expression. Since expression of no more than one *var* gene was associated with Hbec-5i cytoadherence (Table S3), partial correlation only was studied for CHO-ICAM-1. Expression levels of CIDR α 1.4 and DBL β 1/3 in CM isolates and CIDR α 1.4-DBL β 1/3 and CIDR α 1.6 in UM isolates were associated independently with CHO-ICAM-1 cytoadherence. Partial-correlation results are summarized in Table S4.

ICAM-1-binding motif sequencing. Sanger sequencing was performed on isolates with ICAM-1-binding DBL β 1/3 domain expression in reverse transcription-quantitative PCR (RT-qPCR) (34 CM and 38 UM). We obtained 32 DBL β 1/3 sequences (17 CM and 15 UM) with an ICAM-1-binding motif (Table S5). We successfully sequenced 11 CIDR α -ICAM-1-binding DBL β 1/3 dual domains and found that all CIDR α domains were predicted to bind EPCR. A phylogenetic analysis showed no clear association between clinical groups and ICAM-1-binding motif sequence (data not shown).

Recombinant protein sequences and binding property validations. PfEMP1 recombinant domains purity was evaluated by SDS-PAGE and Coomassie blue staining (Fig. S1a) and the domains' sizes were as expected (35 kDa for CIDR α 1.4, 65 kDa for DBL β 3, and 100 kDa for the CIDR α 1.4-DBL β 3 double domain). To ensure the amino acid sequences of our recombinant proteins, a mass spectrometry analysis was carried out (Text S1 and Fig. S1b). All identified peptides matched and covered 70% of the sequence. Furthermore, for the CIDR α 1.4-DBL β 3 domain, a single peptide overlapping both CIDR α 1.4 and DBL β 3 domains was detected (blue highlighting). We validated the interactions between the recombinant domains and the receptors by ligand receptor assay (29) and far-Western blotting (30) (see Text S1 and Fig. S2 and S3).

Assessment of the immune response of children against PfEMP1 subdomains by ELISA. A total of 71 CM and 96 UM plasma samples were tested against ICAM-1-binding motif DBL β ₃_{PF3D7_1150400}, CIDR α 1.4_{PF3D7_1150400}, and dual receptor-binding CIDR α 1.4-DBL β ₃_{PF3D7_1150400} recombinant domains. Significantly, higher IgG levels against DBL β ₃_{PF3D7_1150400} (57 [12 to 107] arbitrary units (AU) versus 44 [0 to 103] AU) ($P = 0.01$) and CIDR α 1.4-DBL β ₃_{PF3D7_1150400} (49 [5 to 101] AU versus 33 [5 to 101] AU) ($P = 0.009$) domains were observed in UM children than in CM children. No difference was found for IgG against CIDR α 1.4 domain (Fig. 3). Among isolates that displayed ICAM-1-binding DBL β 1/3 expression in RT-qPCR, no significant difference in IgG levels was found in CM compared to UM (Fig. 4). Moreover, no difference was observed for UM isolates that expressed or did not express ICAM-1-binding DBL β 1/3 in RT-qPCR. In the same way, UM children carrying a high CIDR α 1.4 level of expression did not have a higher IgG level against CIDR α 1.4_{PF3D7_1150400} than did other children (data not shown).

IgG levels were lower for children with an MR compared to normal fundus (NF) children for both CIDR α 1.4_{PF3D7_1150400} (38 [10 to 65] AU versus 65 [6 to 102] AU) ($P = 0.044$) and CIDR α 1.4-DBL β ₃_{PF3D7_1150400} (33 [0 to 66] AU versus 59 [5 to 101] AU) ($P = 0.028$). Comparing IgG plasma levels between the day of inclusion (D0) and




FIG 4 IgG level against DBLβ3 domain in CM and UM isolates expressing ICAM-1-binding DBLβ1/3 domain in RT-qPCR. Mann-Whitney U-test was used to compare IgG levels for CM and UM children. Scatter plots with median and interquartile range are represented (UM, $n = 38$; CM, $n = 34$).

21 days later (D21) for CM children, IgG levels were significantly higher in D21 plasma (Fig. 5).

DISCUSSION

We conducted a field study in Benin and included children presenting CM and UM. We evaluated the association between *var* gene expression and *in vitro* cytoadherence to Hbec-5i and CHO-ICAM-1 cell lines as well as the prevalence of ICAM-1-binding DBLβ1/3 domain expression.

CM isolates showed higher cytoadherence levels to both cell lines than did UM isolates. Hbec-5i is a well-described but complex cellular model of CM (12, 13) express-




FIG 5 Children's immune kinetics between D0 and D21 to D28 and comparison between malarial retinopathy and normal fundus children. (A) IgG levels of CM with normal fundus or malarial retinopathy. Mann-Whitney U-test was used to compare IgG levels between malarial retinopathy children ($n = 35$) and normal fundus children ($n = 19$). *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.0001$. (B) IgG level against CIDRα1.4_{PF3D7_1150400}, DBLβ3_{PF3D7_1150400} and CIDRα1.4-DBLβ3_{PF3D7_1150400} of CM children at D0 versus D21 ($n = 39$). Wilcoxon matched-pairs signed-rank test was used to evaluate difference between D0 and D21. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.0001$.

ing different membrane receptors such as EPCR, ICAM-1, and PECAM, which could explain a more pronounced variation of cytoadherence than CHO-ICAM-1. These results might be the consequence of the ability of CM isolates to bind to multiple receptors. Higher cytoadherence on CHO-ICAM-1 may result from the nature of transfected cell lines, which express more cell membrane receptors than native ones (31). Our results are consistent with a previous study from Storm et al. (18). However, Hbec-5i and CHO-ICAM-1 are not physiological models of endothelial cells. In addition, although we have validated the cytoadherence assay protocol with a selected HB3 strain, we emphasize that the experiments were performed at room temperature, which could have influenced proteins interaction at the interface between iE and the cellular model.

To investigate the higher cytoadherence capacity of CM isolates, we quantified the expression levels of *var* gene domains. As expected, we did not observe increased CD36-binding domains (CIDR α 2.3/5/6/7/9/10) expression in CM isolates compared to UM isolates. Indeed, CD36-binding properties are a common feature shared by CM and UM isolates and have been rarely described as an explanatory factor in severe malaria pathophysiology (28). Then, we focused on *var* gene domains previously described as overexpressed in CM isolates analyzed by RT-qPCR (18) and transcriptome sequencing (RNA-seq) (32) techniques. CM isolates overexpressed EPCR-binding domains (CIDR α 1.1, CIDR α 1.4-8) and DBL α domains upstream (DBL α 2/1.1/2/4/7) in accordance with the literature, confirming the major role of EPCR in CM pathophysiology (15, 17, 18). Interestingly, DBL ϵ 2, DBL ξ 3, and DBL γ 1 domains were also overexpressed in CM isolates while no binding properties to endothelial receptors have been described for these domains. However, we assume that they could have an impact on the folding or maintenance of PfEMP1 three-dimensional structure as well as in IgM and α 2-macroglobulin binding (33, 34). We might not focus only on domains with known endothelial receptor-binding properties to fully understand CM pathophysiology.

Surprisingly, we did not find any difference in ICAM-1-binding DBL β 1/3 domain expression in RT-qPCR between CM and UM, contrary to previous publications (18, 23). Respectively, 50% and 41% of CM and UM isolates had ICAM-1-binding DBL β 1/3 domain expression in RT-qPCR. As a confirmation, we sequenced the ICAM-1-binding motif in isolates with ICAM-1-binding DBL β 1/3 domain expression and found it in both CM and UM isolates (see Table S5 in the supplemental material). We successfully sequenced the CIDR upstream ICAM-1-binding DBL β 1/3 domain in 11 isolates (9 CM and 2 UM), all predicted to bind EPCR. These results, combined with those of RT-qPCR, pointed out that the ICAM-1-binding DBL β 1/3 domain and dual receptor-binding domains are expressed in both CM and UM isolates, questioning their role in CM physiopathology. Further studies are needed to investigate it more precisely.

In order to quantify the expression and understand the role of dual receptor-binding domains, we successfully designed primers for CIDR α 1.4-DBL β 1/3, CIDR α 1.6-DBL β 1/3 domains and CIDR α 1.7-DBL β 1/3 domains. We had a good coverage on double domains with or without ICAM-1-binding DBL β 1/3 domains (Table S1a). We compared CM and UM isolates with no ICAM-1-binding DBL β 1/3 domain expression in RT-qPCR, and CM isolates had 5-, 13-, and 22-times higher expression of CIDR α 1.4-DBL β 1/3, CIDR α 1.6-DBL β 1/3 and CIDR α 1.7-DBL β 1/3, respectively, than UM isolates, suggesting a possible role of CIDR α 1-DBL β 1/3 domains without ICAM-1-binding motif in CM physiopathology. Inhibition cytoadherence tests of selected *P. falciparum* strains with recombinant CIDR α 1-DBL β 1/3 proteins with or without ICAM-1-binding motif should help to understand the role of this double domain.

To investigate the role of immune response against *var* gene domains in cerebral malaria protection, we measured IgG levels against three recombinant proteins. We hypothesized that UM children infected with parasites expressing ICAM-1-binding DBL β 1/3 domain in RT-qPCR were immunized against that domain and against dual receptor-binding domains. Surprisingly, they did not have a higher IgG level than CM children infected with parasites expressing ICAM-1-binding DBL β 1/3 domain in RT-qPCR, meaning that those UM patients did not seem to be more protected against those domains than CM patients (Fig. 4). However, we tested a single recombinant

protein (PF3D7_1150400, reference sequence) for each domain, and these results must be confirmed with several recombinant proteins with various amino acid sequences.

We carried out fundus examination for each cerebral malaria patient within 1 day of inclusion (35). Of note, 67% of cerebral malaria children had MR. No difference in *var* gene expression and cytoadherence level was evidenced between children with MR and NF (Table S2), as previously described (28). Interestingly, MR children had lower IgG levels against CIDR α 1.4_{PF3D7_1150400} and CIDR α 1.4-DBL β 3_{PF3D7_1150400} than did NF children (Fig. 5). All together, these results suggest the role of immune response against EPCR-binding domains, such as CIDR α 1.4, in MR physiopathology. Finally, we focused on the 10% of CM patients with the highest IgG level against each recombinant protein. We did not find any difference in *var* gene expression compared to the remaining CM patients.

This work showed that CM is associated with parasites presenting a higher level of cytoadherence and EPCR-binding domain expression. Contrary to previous studies, the ICAM-1-binding DBL β 1/3 domain was not overexpressed in CM isolates in comparison to UM isolates. Those isolates expressed dual receptor-binding domains as well as CM. Besides, no difference was found in IgG against DBL β 3_{PF3D7_1150400} between CM and UM isolates that express ICAM-1-binding DBL β 1/3 in RT-qPCR. To conclude, this study raises questions about the role of the A-type ICAM-1-binding domain in CM pathophysiology and finds a potential interest in CIDR α 1-DBL β 1/3 double domains without the ICAM-1-binding motif.

MATERIALS AND METHODS

Recruitment. Ethical clearance has been obtained from Comité National d'Ethique pour la recherche en santé au Bénin (N°67/MS/DC/SGM/DRFMT/CNERS/SA; 17 October 2017) and by Comité consultative de déontologie et d'éthique of Institut de Recherche pour le Développement (IRD; 24 October 2017). Patients were enrolled at Cotonou in southern Bénin from December 2017 to November 2018. We included children between 2 and 6 years displaying either CM or UM. Briefly, we defined UM by fever at inclusion or within 24 h before and positive thick or thin blood smear, without clinical or biological sign of severe malaria. We defined CM by a Blantyre score at diagnosis of ≤ 2 and a confirmed presence of *P. falciparum* infection with exclusion of other causes for coma, particularly meningitis (35). Peripheral venous blood samples have been collected from all study individuals in a Vacutainer tube containing EDTA. Giemsa-stained thick blood film confirmed *P. falciparum* infection, and parasitemia was quantified by counting against 1,000 leukocytes. We separated plasma from total blood by centrifugation and stored it at -20°C . Ring-stage parasites were conserved in TRIzol LS reagent (Life Technologies). Finally, parasites were cultured for 18 h to 24 h *in vitro* to obtain mature forms (Fig. 6) for cytoadherence assays.

DNA extraction. To confirm *P. falciparum* infection by PCR, DNA extraction of isolates was required. Blood samples were extracted with the QIAamp DNA blood minikit (Qiagen) following the manufacturer's instructions. Briefly, 200 μl of whole blood cells from each patient was incubated for 10 min at 56°C with 20 μl of Qiagen protease and 200 μl of lysis buffer. After incubation, 200 μl of ethanol was added and the mix was transferred on silica columns. After several washes with Qiagen buffers, DNA was eluted with 100 μl of elution buffer.

Confirmation of *Plasmodium falciparum* infection and assessment of the MOI. *P. falciparum* identification was confirmed by quantitative PCR (qPCR)-TaqMan (Fast-Track; Launch Diagnostic) following manufacturer's instructions. The MOI was estimated with a fragment analysis method using the *P. falciparum* *msp2* polymorphic gene (36).

RNA collection. *Plasmodium falciparum* RNA preserved in TRIzol LS reagent (Life Technologies) was extracted using the phenol-chloroform method as previously described (37). Briefly, 0.2 ml chloroform was added to 1 ml blood-TRIzol sample, mixed, and then centrifuged at 4°C for 30 min at $12,000 \times g$. Supernatants were precipitated with ice-cold isopropanol and centrifuged as previously described. Pellets containing RNA were recovered with 20 μl RNase-free water. To clean our samples of any potential DNA contamination, RNA samples were digested and purified using the RNeasy minikit (Qiagen) following the manufacturer's guidelines. qPCR on the Rotor-Gene system (Qiagen) was carried out on seryl-tRNA synthetase gene (P90 primers [38]) to assess the absence of remaining parasite genomic DNA. RNA samples were reverse transcribed to cDNA using SuperScript II (Invitrogen; Thermo Fisher Scientific Inc.).

Cytoadherence of isolates on Hbec-5i and CHO-ICAM-1. Static binding assays were carried out on Hbec-5i (cerebral microvascular endothelium from *Homo sapiens* brain, ATCC CRL-3245, USA) and Chinese hamster ovary (CHO) cell lines transfected with ICAM-1 receptor (ATCC CRL-2093, USA). Blood was centrifuged at $800 \times g$ for 20 min for peripheral blood monocellular cell removal. Two hundred to four hundred microliters of ring-stage iE was matured *in vitro* during 24 to 36 h until they reached the mature stages in the first developmental cycle to avoid *var* switching (39). Briefly, isolates were cultured at 10% hematocrit in complete RPMI medium (RPMI 1640 with 0.2 mM hypoxanthine, 0.5% AlbuMAX II [Gibco], 200 μM L-glutamine [Gibco], 25 mM HEPES [Gibco], 10 $\mu\text{g/ml}$ gentamicin [Gibco], and 2% human serum). Mature stages were purified using magnetic columns (MACS cell separation column; Miltenyi

CM diagnosis:

- Positive *P. falciparum* thin blood smear
- Blantyre score ≤ 2 with exclusion factors (35)

UM diagnosis:

- Positive *P. falciparum* thin blood smear and between 1000 to $5 \cdot 10^6$ parasites/ μL
- No clinical or biological sign of severe malaria




FIG 6 Flowchart of the study.

Biotec). All binding assays were performed in triplicate on two different petri dishes (60 × 16 mm, TPP). Thirty-five thousand cells were plated on each spot the day before the cytoadherence experiment. Fifty microliters of an iE suspension of 20% parasitemia and 1% hematocrit in binding buffer (RPMI 1640 with 3% bovine serum albumin [BSA]) was added to each spot and incubated 30 min at room temperature. Unbound erythrocytes were washed off with PBS under 30-rpm agitation on an orbital shaker. Bound erythrocytes were fixed with 1.5% glutaraldehyde in PBS for 1 h and counted microscopically. The number of iE bound to cells was determined by counting 10 fields and expressed as the number of iE bound per square millimeter. Results are expressed as the mean binding level of triplicate spots per sample.

We selected the HB3 strain on Hbec-5i and CHO-ICAM-1 cell lines as previously described (13, 40) and measured their cytoadherence value to validate this assay. We also measured the HB3-ICAM-1 cytoadherence value on CHO parental cell lines to ensure ICAM-1-binding specificity.

var gene expression quantification. Nineteen *var* gene domains were chosen based on previous publications (10, 17, 18, 32), and 122 degenerated primers were designed based on *var* gene sequences assembled (41) from whole-genome sequencing (WGS) of field isolates previously collected in 2014 and 2016 in the same geographical region (1131-Pf-BJ-Bertin, CIVIC study) (32). We evaluated our primer sensitivity on African countries from the MalariaGEN Pf3K data set (Table S1) (42). RT-qPCRs were performed using the SensiFAST Sybr No-ROX kit (Bioline) on the Rotor-Gene qPCR system (Qiagen) following these PCR conditions: 95°C for 2 s; 40 cycles of 95°C for 2 s, 50 to 60°C for 10 s, and 72°C for 10 s; and a dissociation phase from 60°C to 90°C. *var* gene transcript levels were calculated using the relative standard curve method with several plasmid dilutions (GenScript). Quantified domains were normalized with the quantification of the seryl-tRNA synthetase gene expression (38). Human and *P. falciparum* genomic DNAs were used as negative and positive controls, respectively, at each qPCR run.

Sanger sequencing. We looked for the ICAM-1-binding motif ([I/V/L]x3N[E]GG[P/A]xYx27GPPx3H) (23) in DBL β 1/3 RT-qPCR-positive isolates. The first PCR was performed to amplify ICAM-1-binding DBL β 1/3, and the second PCR was performed to amplify CIDR α preceding DBL β 1/3 (Fig. 7). Sanger sequencing of CIDR α -DBL β 1/3 dual receptor-binding domains was performed after purification by gel electrophoresis (NucleoSpin gel and PCR cleanup; Macherey-Nagel).

PfEMP1 domain recombinant protein production. Codon-optimized sequences coding for CIDR α 1.4, DBL β 3, and CIDR α 1.4-DBL β 3 domains from the Pf3D7_1150400 gene were synthesized for *Escherichia coli* (*E. coli*) expression (GenScript). Following the manufacturer's guidelines, these three domains were subcloned in pET100/d-TOPO vector (Invitrogen; Thermo Fisher Scientific) and used to transform TOP10 *E. coli* bacteria. Purified plasmid constructions (PureLink HQ mini-plasmid purification kit; Invitrogen) were confirmed in Sanger sequencing. These plasmids were used to transform Schuffler T7 competent *E. coli* (New England Biolabs). Protein expression was induced by addition of 1 mM IPTG when OD₆₀₀ reached 0.7 (in LB plus 100 $\mu\text{g}/\text{ml}$ ampicillin). Then, cultures were incubated for 4 h at 30°C. Recombinant proteins were purified as previously described (43). Briefly, bacteria were incubated for 2 h at room temperature in lysis buffer (250 mM NaCl, 20 mM Tris, 1 mM DTT, 1× protease inhibitor cocktail




FIG 7 Sanger sequencing analysis of dual receptor binding. We performed PCR targeting the ICAM-1-binding motif in DBL β 1/3 domains with F1, R1, and R2 primers. We sequenced in Sanger sequencing with either R1 or R2 primer (sequence 1). On the basis of sequence 1, we designed a specific primer for each isolate. We performed the second PCR targeting CIDR α ahead of DBL β 1/3 with F2 primer (10) and the primer based on sequence 1 and sequenced with this primer. We looked for dual receptor binding on the reconstruction of CIDR α -DBL β 1/3 sequence.

[Roche] and 2% Sarkosyl). Samples were then sonicated and centrifuged at $3,000 \times g$ for 30 min to pellet cellular fragments. Supernatants were purified on nickel-agarose resin, which specifically binds the histidine tag. Finally, proteins were eluted three times with 2 ml of buffer containing 300 mM imidazole. The purity and the specificity of all our constructions were assessed by mass spectrometry with an Orbitrap Fusion Tribrid (3P5 Cochin Facility) and SDS-PAGE/Coomassie blue staining. We tested the interaction between recombinant proteins and endothelial receptors (ICAM-1 and EPCR) in a ligand receptor assay (29) and a far-Western blotting assay (30) (Text S1).

Mass spectrometry analysis. Digestion was carried out using an S-trap micro spin column. Briefly, samples were heated, reduced, and alkylated at the same time for 5 min at 95°C in a buffer containing 100 mM tetraethylammonium bicarbonate, 2% SDS, 10 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP), and 55 mM chloroacetamide. Then, samples were loaded on S-trap columns and incubated with sequencing-grade-modified trypsin (Promega) overnight at 37°C, and after digestion, peptides were eluted. Mass spectrometry analyses were performed on a Dionex U3000 RSLC nano-LC system coupled to an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientific). After drying, peptides were solubilized in 10 μ l, and 1 μ l was loaded, concentrated, and washed for 3 min on a C₁₈ reverse-phase precolumn. Peptides were separated on a C₁₈ reverse-phase resin with a 1-h gradient ending in 90% of solvent B containing 80% acetonitrile (ACN), 0.085% formic acid (FA) in H₂O. The mass spectrometry data were analyzed using Mascot v2.5 (Matrix Science) jointly on a homemade data bank and on bacteria (333,999 sequences) from the Swiss-Prot data bank containing 560,537 sequences (July 2019). The enzyme specificity was trypsin, and up to 1 missed cleavage was tolerated. Carbamidomethylation of cysteines was set as variable modifications, and oxidation of methionines was set as fixed modifications.

ELISA. Enzyme-linked immunosorbent assays (ELISAs) were performed to measure the total IgG responses against the different PfEMP1 recombinant domains. Briefly, 1 μ g/ml of CIDR α 1.4_{PF3D7_1150400}, DBL β 3_{PF3D7_1150400}, or CIDR α 1.4-DBL β 3_{PF3D7_1150400} recombinant proteins was applied as a coating to MaxiSorp plates (Nunc, Thermo Fisher Scientific) overnight at 4°C. After each step, wells were washed 3 times with PBS-0.1% Tween using an ELISA plate washer. Plates were blocked for 2 h at room temperature with PBS-4% BSA. Then, PBS-diluted plasma samples (1:100) were incubated for 1 h at room temperature and bound IgG was detected using a horseradish peroxidase (HRP)-conjugated mouse anti-human IgG antibody (1:5,000) [IgG(H+L) F(ab')₂-goat anti-human-HRP; Invitrogen]. The HRP substrate 3,3',5,5'-tetramethylbenzidine (TMB Plus2; Eco-Tek) was added for exactly 3 min in darkness, and the reaction was stopped by adding 0.2 M H₂SO₄. Optical densities were measured at 450 nm using the Tecan system. ELISA arbitrary units (AU) were calculated using the following equation: AU = (OD of sample - OD of negative control)/(OD of positive control - OD of negative control) (44). The positive control was a pool of pregnant Beninese women, and the negative control was a pool of plasma from pregnant French women.

Statistical analysis. We compared UM and CM in terms of clinical and biological characteristics, cytoadherence, *var* gene expression, and immune response levels. Nonparametric variables were presented by median (10th to 90th percentile).

Mann-Whitney U-test was used to compare medians of clinical and biological characteristics, cytoadherence, *var* gene expression, and IgG levels and Chi-2 test was used to compare proportions of selected clinical characteristics. Correlations between cytoadherence and *var* gene expression level and between *var* gene expression levels were assessed calculating Spearman's rank correlation coefficient ρ , and *P* values were adjusted (*p*-adj) for multiple testing using the Benjamini-Hochberg correction (45). For a given cytoadherence, when several *var* gene expressions were associated (correlations with a *p*-adj of <0.35), partial correlations were calculated to control for complementary *var* gene expression (46).

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

TEXT S1, DOCX file, 0.02 MB.

FIG S1a, PDF file, 0.2 MB.

FIG S1b, PDF file, 0.4 MB.

FIG S2, PDF file, 0.3 MB.

FIG S3, TIF file, 0.6 MB.

TABLE S1, PDF file, 0.6 MB.

TABLE S2, DOCX file, 0.01 MB.

TABLE S3, XLSX file, 0.04 MB.

TABLE S4, DOCX file, 0.01 MB.

TABLE S5, XLSX file, 0.01 MB.

ACKNOWLEDGMENTS

We are grateful to all patients and their parents for participating in this study. We are thankful to the nurses of the CHU-MEL hospital (CHU-Mère et Enfant de la Lagune) and Hôpital de zone de Calavi for their help in the collection of samples. We also thank the health center of So-Ava. We thank Nadine Fievet for her help in the recruitment of the subjects. We thank Matt Berriman, Chris Newbold, and Thomas Otto for their help in assembled *var* gene analysis. We thank Cédric Broussard from the 3P5 proteomic platform (Université de Paris, Institut Cochin, INSERM, U1016, CNRS, UMR8104, Paris, France). We recognize and thank Inovarion as the employer of E.G. Finally, we thank all the members of the NeuroCM group for their contribution to the project.

NeuroCM group: Dissou Affolabi (Pediatric Department, Calavi Hospital, Calavi, Benin); Linda Ayedadjou (Pediatric Department, Mother and Child University and Hospital Center [CHU-MEL], Cotonou, Benin); Bibiane Biokou (Pediatric Department, Mother and Child University and Hospital Center [CHUMEL], Cotonou, Benin); Lisa Casañas (Université de Paris, MERIT, IRD, Paris, France); Jean-Eudes Degbelo (Calavi Hospital, Calavi, Benin); Philippe Deloron (Université de Paris, MERIT, IRD, Paris, France); Latifou Dramane (IRCB, Cotonou, Bénin); Claire Kamaliddin (Université de Paris, MERIT, IRD, Paris, France); Elisée Kinkpe (Pediatric Department, Calavi Hospital, Calavi, Benin); Anaïs Labrunie (Université de Limoges, NET, INSERM, Limoges, France); Yélé Ladipo (Pediatric Department, Mother and Child University and Hospital Center [CHUMEL], Cotonou, Benin); Thomas Lathiere (Ophthalmology Department, Limoges University Hospital, Limoges, France); Audrey Mowendabeka (Pediatric Department, Hospital de la Mère et de l'Enfant, Limoges, France); Jade Papin (Université de Paris, MERIT, IRD, Paris, France); Bernard Pipy (Université de Toulouse, PHARMADEV, IRD, UPS, Toulouse, France); Pierre-Marie Preux (Université de Limoges, NET, INSERM, Limoges, France); Marie Raymondeau (Université de Limoges, NET, INSERM, Limoges, France); Jade Royo (PHARMADEV, Université de Toulouse, IRD, UPS, France); Darius Sossou (IRCB, Cotonou, Bénin); Brigitte Techer (Université de Paris, MERIT, IRD, Paris, France).

V.J.: wrote the article; designed the study; performed the experiments; data analysis. E.G.: wrote the article; bioinformatic methodology; data analysis. J.F.: wrote the article; performed the experiments; data analysis. B.V.: performed the experiments. S.J.-G.: designed and performed the MOI experiment. J.F.F. and S.H.: supervised patients' recruitment and clinical analysis. L.W. and M.C.: statistical analysis. A.A.: supervised patients' recruitment. N.A.: designed the study; supervised the experiments. G.I.B.: supervised the experiments; wrote the article; designed the study and data analysis.

This work was funded by the French National Research Agency (ANR-17-CE17-0001).

There are no conflicts of interest to disclose.

REFERENCES

- World Health Organization. 2019. World malaria report 2019. World Health Organization, Geneva, Switzerland.
- Miller LH, Baruch DI, Marsh K, Doumbo OK. 2002. The pathogenic basis of malaria. *Nature* 415:673–679. <https://doi.org/10.1038/415673a>.
- Seydel KB, Kampondeni SD, Valim C, Potchen MJ, Milner DA, Muwalo FW, Birbeck GL, Bradley WG, Fox LL, Glover SJ, Hammond CA, Heyderman RS, Chilingulo CA, Molyneux ME, Taylor TE. 2015. Brain swelling and death in children with cerebral malaria. *N Engl J Med* 372:1126–1137. <https://doi.org/10.1056/NEJMoa1400116>.
- Beare NAV, Taylor TE, Harding SP, Lewallen S, Molyneux ME. 2006. Malarial

- retinopathy: a newly established diagnostic sign in severe malaria. *Am J Trop Med Hyg* 75:790–797. <https://doi.org/10.4269/ajtmh.2006.75.790>.
5. Barrera V, MacCormick JC, Czanner G, Hiscott PS, White VA, Craig AG, Beare NAV, Culshaw LH, Zheng Y, Biddolph SC, Milner DA, Kamiza S, Molyneux ME, Taylor TE, Harding SP. 2018. Neurovascular sequestration in paediatric *P falciparum* malaria is visible clinically in the retina. *Elife* 7:e32208. <https://doi.org/10.7554/eLife.32208>.
 6. Su XZ, Heatwole VM, Wertheimer SP, Guinet F, Herrfeldt JA, Peterson DS, Ravetch JA, Wellems TE. 1995. The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of *Plasmodium falciparum*-infected erythrocytes. *Cell* 82:89–100. [https://doi.org/10.1016/0092-8674\(95\)90055-1](https://doi.org/10.1016/0092-8674(95)90055-1).
 7. Lavstsen T, Salanti A, Jensen ATR, Arnot DE, Theander TG. 2003. Subgrouping of *Plasmodium falciparum* 3D7 var genes based on sequence analysis of coding and non-coding regions. *Malar J* 2:27. <https://doi.org/10.1186/1475-2875-2-27>.
 8. Jensen ATR, Magistrado P, Sharp S, Joergensen L, Lavstsen T, Chiucciuini A, Salanti A, Vestergaard LS, Lusingu JP, Hermesen R, Sauerwein R, Christensen J, Nielsen MA, Hviid L, Sutherland C, Staalsoe T, Theander TG. 2004. *Plasmodium falciparum* associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes. *J Exp Med* 199:1179–1190. <https://doi.org/10.1084/jem.20040274>.
 9. Kaestli M, Cockburn IA, Cortés A, Baea K, Rowe JA, Beck H-P. 2006. Virulence of malaria is associated with differential expression of *Plasmodium falciparum* var gene subgroups in a case-control study. *J Infect Dis* 193:1567–1574. <https://doi.org/10.1086/503776>.
 10. Lavstsen T, Turner L, Saguti F, Magistrado P, Rask TS, Jespersen JS, Wang CW, Berger SS, Baraka V, Marquard AM, Seguin-Orlando A, Willerslev E, Gilbert MTP, Lusingu J, Theander TG. 2012. *Plasmodium falciparum* erythrocyte membrane protein 1 domain cassettes 8 and 13 are associated with severe malaria in children. *Proc Natl Acad Sci U S A* 109: E1791–1800. <https://doi.org/10.1073/pnas.1120455109>.
 11. Rask TS, Hansen DA, Theander TG, Pedersen AG, Lavstsen T. 2010. *Plasmodium falciparum* erythrocyte membrane protein 1 diversity in seven genomes – divide and conquer. *PLoS Comput Biol* 6:e1000933. <https://doi.org/10.1371/journal.pcbi.1000933>.
 12. Avril M, Tripathi AK, Brazier AJ, Andisi C, Janes JH, Soma VL, Sullivan DJ, Bull PC, Stins MF, Smith JD. 2012. A restricted subset of var genes mediates adherence of *Plasmodium falciparum*-infected erythrocytes to brain endothelial cells. *Proc Natl Acad Sci U S A* 109:E1782–1790. <https://doi.org/10.1073/pnas.1120534109>.
 13. Claessens A, Adams Y, Ghumra A, Lindergard G, Buchan CC, Andisi C, Bull PC, Mok S, Gupta AP, Wang CW, Turner L, Arman M, Raza A, Bozdech Z, Rowe JA. 2012. A subset of group A-like var genes encodes the malaria parasite ligands for binding to human brain endothelial cells. *Proc Natl Acad Sci U S A* 109:E1772–1781. <https://doi.org/10.1073/pnas.1120461109>.
 14. Reference deleted.
 15. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JEV, Avril M, Brazier AJ, Freeth J, Jespersen JS, Nielsen MA, Magistrado P, Lusingu J, Smith JD, Higgins MK, Theander TG. 2013. Severe malaria is associated with parasite binding to endothelial protein C receptor. *Nature* 498:502–505. <https://doi.org/10.1038/nature12216>.
 16. Lau CKY, Turner L, Jespersen JS, Lowe ED, Petersen B, Wang CW, Petersen JEV, Lusingu J, Theander TG, Lavstsen T, Higgins MK. 2015. Structural conservation despite huge sequence diversity allows EPCR binding by the PfEMP1 family implicated in severe childhood malaria. *Cell Host Microbe* 17:118–129. <https://doi.org/10.1016/j.chom.2014.11.007>.
 17. Mkumbaye SI, Wang CW, Lyimo E, Jespersen JS, Manjurano A, Moshia J, Kavishe RA, Mwakalinga SB, Minja DTR, Lusingu JP, Theander TG, Lavstsen T. 2017. The severity of *Plasmodium falciparum* infection is associated with transcript levels of var genes encoding endothelial protein C receptor-binding P. falciparum erythrocyte membrane protein 1. *Infect Immun* 85:e00841–16. <https://doi.org/10.1128/IAI.00841-16>.
 18. Storm J, Jespersen JS, Seydel KB, Szeszak T, Mbewe M, Chisala NV, Phula P, Wang CW, Taylor TE, Moxon CA, Lavstsen T, Craig AG. 2019. Cerebral malaria is associated with differential cytoadherence to brain endothelial cells. *EMBO Mol Med* 11:e9164. <https://doi.org/10.15252/emmm.201809164>.
 19. Tuikue Ndam N, Moussiliou A, Lavstsen T, Kamaliddin C, Jensen ATR, Mama A, Tahar R, Wang CW, Jespersen JS, Alao JM, Gamain B, Theander TG, Deloron P. 2017. Parasites causing cerebral *Falciparum* malaria bind multiple endothelial receptors and express EPCR and ICAM-1-binding PfEMP1. *J Infect Dis* 215:1918–1925. <https://doi.org/10.1093/infdis/jix230>.
 20. Gillrie MR, Avril M, Brazier AJ, Davis SP, Stins MF, Smith JD, Ho M. 2015. Diverse functional outcomes of *Plasmodium falciparum* ligation of EPCR: potential implications for malarial pathogenesis. *Cell Microbiol* 17: 1883–1899. <https://doi.org/10.1111/cmi.12479>.
 21. Silamut K, Phu NH, Whitty C, Turner G, Louwrier K, Mai NT, Simpson JA, Hien TT, White NJ. 1999. A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. *Am J Pathol* 155:395–410. [https://doi.org/10.1016/S0002-9440\(10\)65136-X](https://doi.org/10.1016/S0002-9440(10)65136-X).
 22. Avril M, Bernabeu M, Benjamin M, Brazier AJ, Smith JD. 2016. Interaction between endothelial protein C receptor and intercellular adhesion molecule 1 to mediate binding of *Plasmodium falciparum*-infected erythrocytes to endothelial cells. *mBio* 7:e00615-16. <https://doi.org/10.1128/mBio.00615-16>.
 23. Lennartz F, Adams Y, Bengtsson A, Olsen RW, Turner L, Ndam NT, Ecklu-Mensah G, Moussiliou A, Ofori MF, Gamain B, Lusingu JP, Petersen JEV, Wang CW, Nunes-Silva S, Jespersen JS, Lau CKY, Theander TG, Lavstsen T, Hviid L, Higgins MK, Jensen ATR. 2017. Structure-guided identification of a family of dual receptor-binding PfEMP1 that is associated with cerebral malaria. *Cell Host Microbe* 21:403–414. <https://doi.org/10.1016/j.chom.2017.02.009>.
 24. Lennartz F, Bengtsson A, Olsen RW, Joergensen L, Brown A, Remy L, Man P, Forest E, Barfod LK, Adams Y, Higgins MK, Jensen ATR. 2015. Mapping the binding site of a cross-reactive *Plasmodium falciparum* PfEMP1 monoclonal antibody inhibitory of ICAM-1 binding. *J Immunol* 195: 3273–3283. <https://doi.org/10.4049/jimmunol.1501404>.
 25. Oleinikov AV, Amos E, Frye IT, Rosssnagle E, Mutabingwa TK, Fried M, Duffy PE. 2009. High throughput functional assays of the variant antigen PfEMP1 reveal a single domain in the 3D7 *Plasmodium falciparum* genome that binds ICAM1 with high affinity and is targeted by naturally acquired neutralizing antibodies. *PLoS Pathog* 5:e1000386. <https://doi.org/10.1371/journal.ppat.1000386>.
 26. Jensen AR, Adams Y, Hviid L. 2020. Cerebral *Plasmodium falciparum* malaria: the role of PfEMP1 in its pathogenesis and immunity, and PfEMP1-based vaccines to prevent it. *Immunol Rev* 293:230–252. <https://doi.org/10.1111/immr.12807>.
 27. Fleckenstein H, Portugal S. 2019. Binding brain better-matching var genes and endothelial receptors. *EMBO Mol Med* 11:e10137. <https://doi.org/10.15252/emmm.201810137>.
 28. Heddi A, Pettersson F, Kai O, Shafi J, Obiero J, Chen Q, Barragan A, Wahlgren M, Marsh K. 2001. Fresh isolates from children with severe *Plasmodium falciparum* malaria bind to multiple receptors. *Infect Immun* 69:5849–5856. <https://doi.org/10.1128/iai.69.9.5849-5856.2001>.
 29. Syedbasha M, Linnik J, Santer D, O'Shea D, Barakat K, Joyce M, Khanna N, Tyrrell DL, Houghton M, Egli A. 2016. An ELISA based binding and competition method to rapidly determine ligand-receptor interactions. *J Vis Exp* (109):53575. <https://doi.org/10.3791/53575>.
 30. Wu Y, Li Q, Chen X-Z. 2007. Detecting protein-protein interactions by far western blotting. *Nat Protoc* 2:3278–3284. <https://doi.org/10.1038/nprot.2007.459>.
 31. Azasi Y, Lindergard G, Ghumra A, Mu J, Miller LH, Rowe JA. 2018. Infected erythrocytes expressing DC13 PfEMP1 differ from recombinant proteins in EPCR-binding function. *Proc Natl Acad Sci U S A* 115:1063–1068. <https://doi.org/10.1073/pnas.1712879115>.
 32. Kamaliddin C, Rombaut D, Guillochon E, Royo J, Ezinmegnon S, Agbota G, Huguet S, Guemouri S, Peirera C, Coppée R, Broussard C, Alao JM, Aubouy A, Guillonneau F, Deloron P, Bertin GI. 2019. From genomic to LC-MS/MS evidence: analysis of PfEMP1 in Benin malaria cases. *PLoS One* 14:e0218012. <https://doi.org/10.1371/journal.pone.0218012>.
 33. Jeppesen A, Ditlev SB, Soroka V, Stevenson L, Turner L, Dzikowski R, Hviid L, Barfod L. 2015. Multiple *Plasmodium falciparum* erythrocyte membrane protein 1 variants per genome can bind IgM via its Fc fragment Fc μ . *Infect Immun* 83:3972–3981. <https://doi.org/10.1128/IAI.00337-15>.
 34. Stevenson L, Huda P, Jeppesen A, Laursen E, Rowe JA, Craig A, Streicher W, Barfod L, Hviid L. 2015. Investigating the function of Fc-specific binding of IgM to *Plasmodium falciparum* erythrocyte membrane protein 1 mediating erythrocyte rosetting. *Cell Microbiol* 17:819–831. <https://doi.org/10.1111/cmi.12403>.
 35. Joste V, Maurice L, Bertin GI, Aubouy A, Boumédiène F, Houzé S, Ajzenberg D, Argy N, Massougbdji A, Dossou-Dagba I, Alao MJ, Cot M, Deloron P, Faucher J-F, NeuroCM group. 2019. Identification of *Plasmodium falciparum* and host factors associated with cerebral malaria: description of the protocol for a prospective, case-control study in Benin (NeuroCM). *BMJ Open* 9:e027378. <https://doi.org/10.1136/bmjopen-2018-027378>.
 36. Jafari S, Le Bras J, Bouchaud O, Durand R. 2004. *Plasmodium falciparum* clonal population dynamics during malaria treatment. *J Infect Dis* 189: 195–203. <https://doi.org/10.1086/380910>.
 37. Rio DC, Ares M, Hannon GJ, Nilsen TW. 2010. Purification of RNA using

- TRIzol (TRI reagent). Cold Spring Harb Protoc 2010;pdb.prot5439. <https://doi.org/10.1101/pdb.prot5439>.
38. Salanti A, Staalsoe T, Lavstsen T, Jensen ATR, Sowa MPK, Arnot DE, Hviid L, Theander TG. 2003. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering *Plasmodium falciparum* involved in pregnancy-associated malaria. *Mol Microbiol* 49: 179–191. <https://doi.org/10.1046/j.1365-2958.2003.03570.x>.
 39. Scherf A, Hernandez-Rivas R, Buffet P, Bottius E, Benatar C, Pouvelle B, Gysin J, Lanzer M. 1998. Antigenic variation in malaria: in situ switching, relaxed and mutually exclusive transcription of var genes during intra-erythrocytic development in *Plasmodium falciparum*. *EMBO J* 17: 5418–5426. <https://doi.org/10.1093/emboj/17.18.5418>.
 40. Claessens A, Rowe JA. 2012. Selection of *Plasmodium falciparum* parasites for cytoadhesion to human brain endothelial cells. *J Vis Exp* (59): e3122. <https://doi.org/10.3791/3122>.
 41. Otto TD, Assefa SA, Böhme U, Sanders MJ, Kwiatkowski D, Berriman M, Newbold C, Pf3k consortium. 2019. Evolutionary analysis of the most polymorphic gene family in *falciparum* malaria. *Wellcome Open Res* 4:193. <https://doi.org/10.12688/wellcomeopenres.15590.1>.
 42. Pearson RD, Amato R, Kwiatkowski DP, MalariaGEN *Plasmodium falciparum* Community Project. 2019. An open dataset of *Plasmodium falciparum* genome variation in 7,000 worldwide samples. bioRxiv 824730. <https://www.biorxiv.org/content/10.1101/824730v1>.
 43. Massiah MA, Wright KM, Du H. 2016. Obtaining soluble folded proteins from inclusion bodies using Sarkosyl, Triton X-100, and CHAPS: application to LB and M9 minimal media. *Curr Protoc Protein Sci* 84: 6.13.1–6.13.24. <https://doi.org/10.1002/0471140864.ps0613s84>.
 44. Olsen RW, Ecklu-Mensah G, Bengtsson A, Ofori MF, Lusingu JPA, Castberg FC, Hviid L, Adams Y, Jensen ATR. 2018. Natural and vaccine-induced acquisition of cross-reactive IgG-inhibiting ICAM-1-specific binding of a *Plasmodium falciparum* PfEMP1 subtype associated specifically with cerebral malaria. *Infect Immun* 86:e00622-17. <https://doi.org/10.1128/IAI.00622-17>.
 45. Hochberg Y, Benjamini Y. 1990. More powerful procedures for multiple significance testing. *Stat Med* 9:811–818. <https://doi.org/10.1002/sim.4780090710>.
 46. Kendall MG, Stuart A. 1973. *The advanced theory of statistics*, 3rd ed. Charles Griffin, London, United Kingdom.